By submitting this form, you are agreeing to the Terms of Use and Privacy Policy.
Safinamide, a medication having many mechanisms of action, is used as an additional therapy for Parkinson’s disease with “off” episodes. One of these mechanisms is the inhibition of monoamine oxidase B.
Levodopa/carbidopa and safinamide are combined to treat the symptoms of Parkinson’s disease. It can aid in alleviating symptoms like trembling, stiffness, and difficulty moving.
Additionally, it may aid in minimising “off” time (periods of slow movement or stiffness). Safinamide is a member of the MAO inhibitor drug subclass.
It functions by raising the concentrations of specific natural chemicals in the brain (such as dopamine). Too little dopamine in the brain is assumed to be the cause of Parkinson’s disease.
If you have any allergies, including to safinamide, make sure to let your doctor or pharmacist know before taking any medication. Inactive chemicals in this product have the potential to trigger allergic reactions or other issues.
People with significant liver impairment, albinism, retinitis pigmentosa, severe diabetic neuropathy, uveitis, and other retinal problems should not take safinamide. Pethidine and other monoamine oxidase (MAO) inhibitors should not be combined.
Nausea, vertigo, exhaustion, insomnia, orthostatic hypotension (low blood pressure), and headache were common side effects in clinical trials (in greater than 1% of participants). Between safinamide and placebo, there was no discernible difference in the frequency of these side events.
Global SAFINAMIDE market accounted for $XX Billion in 2023 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030.
Safinamide, also known by the brand name Xadago, was introduced by Zambon and its business partner Newron Pharmaceuticals in the UK.
Safinamide enhanced quality of life and mood while reducing “off” periods—when medication stops working—without raising the risk of dyskinesia.
Safinamide is an MAO-B inhibitor and, like other drugs already in use, stops the enzyme monoamine oxidase type B (MAO-B) from degrading dopamine.
This new medication, however, inhibits the MAO-B enzyme in a slightly different manner, which might increase its efficacy in the treatment of Parkinson’s.
Safinamide serves the same purpose as certain already available Parkinson’s medications, therefore your doctor will only recommend it when necessary.
